newsio aggregates and links to original sources. We do not own the original images or content. If you believe content infringes on intellectual property rights, contact us — it will be removed at first notice.

biotech / news / / STAT

The pill, dubbed MK 8527, is currently undergoing a pair of late-stage clinical trials.

Merck's experimental HIV prevention pill could be produced for under $5 per patient annually.

KEY POINTS
COMPANIES
Read the full story on STAT →
Share X LinkedIn

Summarized by Newsio from STAT. How we summarize →